

Special Issue

Natural Products Based Anticancer Drugs

Message from the Guest Editors

The study of the anticancer potential of natural origin substances is a legitimate research direction. Indeed, plant-derived compounds, such as paclitaxel, vincristine, or those produced by the bacteria doxorubicin, are still used in treating various neoplasms. An increasing number of studies show that natural origin substances act by regulating molecular pathways, which are implicated in the growth and progression of cancer. Therefore, they represent a promising strategy to complement conventional cancer treatments.

This Special Issue aims to disseminate the results of research on natural origin substances (compounds and characterized extracts) that may be of legitimate importance in developing new drugs for antitumor therapy. The aim is to identify new agents against human cancers and evaluate their mechanisms of action. Research into new pharmaceutical formulations based on natural origin, anticancer, biologically active substances is also a valuable approach for the progress of novel anticancer drugs. Hence, we welcome original research and review articles focused on the anticancer potential of natural substances in regard to their use as an anticancer drug.

Guest Editors

Dr. Elżbieta Studzińska-Sroka

Department of Pharmacognosy and Biomaterials, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland

Dr. Aleksandra Majchrzak-Celińska

Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, 60-806 Poznan, Poland

Deadline for manuscript submissions

closed (31 August 2024)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/155985

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).